Article
Oncology
Sara Alonso-Alvarez, Martina Manni, Silvia Montoto, Clementine Sarkozy, Franck Morschhauser, Marielle J. Wondergem, Attilio Guarini, Laura Magnano, Miguel Alcoceba, Martine Chamuleau, Sara Galimberti, Maria Gomes da Silva, Harald Holte, Emanuele Zucca, Sandra Lockmer, Igor Aurer, Luigi Marcheselli, Yana Stepanishyna, Maria Dolores Caballero Barrigon, Gilles Salles, Massimo Federico
Summary: Patients with PREF FL have a significantly increased risk of histological transformation, poor prognosis, and lower survival rates compared to other FL patients.
EUROPEAN JOURNAL OF CANCER
(2021)
Letter
Oncology
Jie Zha, Liyuan Fan, Shuhua Yi, Haifeng Yu, Zhong Zheng, Wei Xu, Manman Deng, Zhijuan Lin, Zhifeng Li, Lingyan Ping, Xiaohua He, Feili Chen, Ying Xie, Biyun Chen, Huilai Zhang, Li Wang, Kaiyang Ding, Wenyu Li, Haiyan Yang, Weili Zhao, Lugui Qiu, Zhiming Li, Yuqin Song, Bing Xu
Summary: This study analyzed the clinical characteristics and outcomes of FL patients in China, revealing differences in features between Chinese and Western patients but similar overall prognosis. Adding rituximab to treatment led to the best outcomes, while histologic transformation was associated with poor survival.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2021)
Article
Hematology
Kostiantyn Dreval, Laura K. Hilton, Manuela Cruz, Haya Shaalan, Susana Ben-Neriah, Merrill Boyle, Brett Collinge, Krysta M. Coyle, Gerben Duns, Pedro Farinha, Bruno M. Grande, Barbara Meissner, Prasath Pararajalingam, Christopher K. Rushton, Graham W. Slack, Jasper Wong, Andrew J. Mungall, Marco A. Marra, Joseph M. Connors, Christian Steidl, David W. Scott, Ryan D. Morin
Summary: Follicular lymphoma (FL) accounts for approximately 20% of new lymphoma cases. In this study, two genetically distinct subgroups of FL, called DLBCL-like (dFL) and constrained FL (cFL), were identified and characterized based on whole-genome sequencing data. Using a machine learning approach, patients with FL could be stratified into cFL and dFL subgroups, and it was found that cFL status is associated with a reduced risk of lymphoma transformation.
Article
Oncology
Aino Rajamaki, Mika Hujo, Reijo Sund, Roosa E. I. Prusila, Milla E. L. Kuusisto, Hanne Kuitunen, Esa Jantunen, Santiago Mercadal, Marc Sorigue, Juan-Manuel Sancho, Kaisa Sunela, Outi Kuittinen
Summary: This study examined the proportion of deaths from progressive lymphoma and the impact of follicular lymphoma (FL) on survival. The results showed that deaths from progressive lymphoma are nearly as common as deaths from other causes in FL patients during the rituximab era. Despite improvements in survival, there was evidence of excess mortality resulting from FL for at least 10 years after diagnosis.
Article
Hematology
Alden Alberto Moccia, Saemi Schaer, Stefanie Hayoz, Maria Cristina Pirosa, Christian Taverna, Urban Novak, Eva Kimby, Michele Ghielmini, Emanuele Zucca
Summary: The relapse of follicular lymphoma within 24 months of chemoimmunotherapy is associated with poor survival, and the POD24 remains a prognostic factor even in patients treated without chemotherapy.
BRITISH JOURNAL OF HAEMATOLOGY
(2021)
Article
Oncology
Makoto Saito, Akio Mori, Shihori Tsukamoto, Takashi Ishio, Emi Yokoyama, Koh Izumiyama, Masanobu Morioka, Takeshi Kondo, Hirokazu Sugino
Summary: Treatment intervention in Stage IV D-FL patients has shown success, but long-term recurrence is possible. The study highlights the need for establishing treatment criteria for advanced D-FL based on more cases and emphasizes the importance of long-term follow-up examinations.
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY
(2022)
Article
Oncology
Hideki Uryu, Yuko Mishima, Naoko Tsuyama, Masahiro Yokoyama, Noriko Nishimura, Takanori Fukuta, Yuko Shirouchi, Takashi Okabe, Norihito Inoue, Kengo Takeuchi, Yasuhito Terui
Summary: The study shows that rituximab maintenance therapy can improve the prognosis of patients with concurrent-DLBCL/FL, leading to better overall survival, progression-free survival, and reduced risk of relapse. Additionally, concurrent-DLBCL/FL demonstrates better survival outcomes after recurrence.
LEUKEMIA & LYMPHOMA
(2021)
Review
Oncology
Yurou Chu, Yingyue Liu, Zhuoya Yu, Linquan Zhan, Tiange Lu, Yujie Jiang, Xiaosheng Fang, Xiangxiang Zhou, Xin Wang
Summary: This study conducted a systematic review and meta-analysis to evaluate the maintenance or consolidation strategy for patients with advanced follicular lymphoma. The results showed that obinutuzumab and rituximab maintenance treatment significantly improved progression-free survival (PFS). However, further validation in larger populations is needed to confirm the clinical benefit.
Article
Oncology
Gwladys Claustre, Coralie Boulanger, Frederic Maloisel, Nelly Etienne-Selloum, Luc-Matthieu Fornecker, Eric Durot, Florian Slimano, Veronique Graff
Summary: This study compared the efficacy and safety of R-CHOP and G-CHOP treatments for previously untreated FL, and assessed the economic impact of introducing G. The results showed no significant difference in PFS between the two treatment strategies, but the G-CHOP group had higher hematological toxicity and infusion-related reactions during induction treatment. The introduction of G treatment resulted in additional costs per patient. Further studies including quality of life data are recommended.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Hematology
Tamar Berger, Tzippy Shochat, Shlomzion Aumann, Boaz Nachmias, Neta Goldschmidt, Nurit Horesh, Reut Harel, Ariel Aviv, Ella Shmerts, Uri Abadi, Shai Shimony, Pia Raanani, Anat Gafter-Gvili, Ronit Gurion
Summary: The GALLIUM study found that obinutuzumab-based immunochemotherapies showed a 7% progression-free survival advantage over rituximab-based therapies as first-line treatment for follicular lymphoma patients. However, obinutuzumab-based therapy was associated with increased toxicity. This multicenter retrospective-cohort study compared the toxicity of rituximab and obinutuzumab-based chemo-immunotherapies in adult FL patients and found no significant difference in infection rates and adverse events between the two groups during the induction and post-induction period.
ANNALS OF HEMATOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Nathan Hale Fowler, Michael Dickinson, Martin Dreyling, Joaquin Martinez-Lopez, Arne Kolstad, Jason Butler, Monalisa Ghosh, Leslie Popplewell, Julio C. Chavez, Emmanuel Bachy, Koji Kato, Hideo Harigae, Marie Jose Kersten, Charalambos Andreadis, Peter A. Riedell, P. Joy Ho, Jose Antonio Perez-Simon, Andy Chen, Loretta J. Nastoupil, Bastian von Tresckow, Andres Jose Maria Ferreri, Takanori Teshima, Piers E. M. Patten, Joseph P. McGuirk, Andreas L. Petzer, Fritz Offner, Andreas Viardot, Pier Luigi Zinzani, Ram Malladi, Aiesha Zia, Rakesh Awasthi, Aisha Masood, Oezlem Anak, Stephen J. Schuster, Catherine Thieblemont
Summary: Tisagenlecleucel, an autologous anti-CD19 CAR-T cell therapy, demonstrated a high complete response rate of 69.1% and overall response rate of 86.2% in adults with relapsed or refractory follicular lymphoma. Adverse events post-treatment primarily included cytokine release syndrome and neurological events, with no treatment-related deaths reported.
Article
Oncology
Terry Boyle, Geffen Kleinstern, Paige M. Bracci, James R. Cerhan, Yolanda Benavente, Delphine Casabonne, Brian C-H Chiu, Thomas M. Habermann, Elizabeth A. Holly, Mark Liebow, Aaron Norman, Ora Paltiel, Dennis Robinson, Nathaniel Rothman, Rania Abu Seir, Susan L. Slager, Paul J. Villeneuve, Sophia S. Wang, Dennis D. Weisenburger, John J. Spinelli
Summary: This study, which pooled data from nine case-control studies, found that moderate-to-vigorous intensity physical activity can reduce the risk of non-Hodgkin lymphoma.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Article
Hematology
Emmanuel Bachy, Roch Houot, Pierre Feugier, Krimo Bouabdallah, Reda Bouabdallah, Emmanuelle Nicolas Virelizier, Marie Maerevoet, Christophe Fruchart, Sylvia Snauwaert, Steven Le Gouill, Jean-Pierre Marolleau, Lysiane Molina, Cecile Molucon-Chabrot, Catherine Thieblemont, Herve Tilly, Fontanet Bijou, Corinne Haioun, Eric Van den Neste, Bettina Fabiani, Michel Meignan, Guillaume Cartron, Gilles Salles, Olivier Casasnovas, Franck Morschhauser
Summary: The combination of Obinutuzumab and lenalidomide has shown promising clinical efficacy and a manageable safety profile in various types of lymphoma. This study reported the efficacy and safety results for previously untreated patients with advanced follicular lymphoma. The combination treatment resulted in a high complete response rate, overall response rate, and favorable progression-free survival and overall survival. The most common adverse event was neutropenia.
Article
Hematology
W. Richard Burack, Hongli Li, Diana Adlowitz, Janice M. Spence, Lisa M. Rimsza, Mazyar Shadman, Catherine M. Spier, Mark S. Kaminski, John P. Leonard, Michael L. Leblanc, Sonali M. Smith, Jonathan W. Friedberg
Summary: Subclonal TP53 mutations are common in follicular lymphoma and are distinct from AICDA-mediated genetic heterogeneity. Patients with no detectable subclonal mutation in TP53 benefit particularly from RIT.
Article
Oncology
Carla Casulo, Michael Herold, Wolfgang Hiddemann, Sunil Iyengar, Robert E. Marcus, John F. Seymour, Aino Launonen, Andrea Knapp, Tina G. Nielsen, Farheen Mir
Summary: In order to improve patient management for follicular lymphoma (FL), more information on histological transformation (HT) incidence, risk factors, and outcomes is needed. The GALLIUM study showed that HT was a low-frequency event (3.3%), but associated with poor survival. Male sex and elevated baseline serum levels of lactate dehydrogenase and /32-microglobulin were significant risk factors for HT.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2023)
Article
Hematology
Alessandra Tucci, Francesco Merli, Alberto Fabbri, Luigi Marcheselli, Chiara Pagani, Benedetta Puccini, Dario Marino, Manuela Zanni, Elsa Pennese, Leonardo Flenghi, Annalisa Arcari, Barbara Botto, Melania Celli, Caterina Mammi, Alessandro Re, Giulia Campostrini, Agostino Tafuri, Vittorio R. Zilioli, Emanuele Cencini, Roberto Sartori, Chiara Bottelli, Michele Merli, Luigi Petrucci, Guido Gini, Monica Balzarotti, Federica Cavallo, Gerardo Musuraca, Stefano Luminari, Giuseppe Rossi, Michele Spina
Summary: Octogenarian patients with diffuse large B-cell lymphoma are mainly managed with palliation, but recent improvement in their condition allows for potentially curative treatment. Studies show that selected octogenarians can be cured with reduced-dose anthracycline chemoimmunotherapy. However, patients over 85 years old are underrepresented in the studies and selection criteria are unclear. This study analyzes the characteristics and outcomes of late octogenarian patients enrolled in the FIL Elderly Project, comparing them with early octogenarians and older patients classified as unfit or frail. Late octogenarians more frequently receive palliative treatment and have worse overall survival and progression-free survival compared to early octogenarians.
Article
Oncology
Olivier Hermine, Linmiao Jiang, Jan Walewski, Andre Bosly, Catherine Thieblemont, Michal Szymczyk, Christiane Pott, Gilles Salles, Pierre Feugier, Kai Hubel, Corinne Haioun, Rene Olivier Casasnovas, Christian Schmidt, Kamal Bouabdallah, Vincent Ribrag, Lothar Kanz, Jan Durig, Bernd Metzner, David Sibon, Morgane Cheminant, Barbara Burroni, Wolfram Klapper, Wolfgang Hiddemann, Michael Unterhalt, Eva Hoster, Martin Dreyling
Summary: Clinical Trial Updates provide an opportunity to disseminate additional results from studies for which the primary end point has already been reported. This study confirms the previously observed substantially prolonged time to treatment failure and shows an improvement in overall survival for patients with Mantle Cell Lymphoma. Some patients with MCL may be cured.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Ana Alarcon Tomas, Joshua A. Fein, Shalev Fried, Jessica R. Flynn, Sean M. Devlin, Warren B. Fingrut, Theodora Anagnostou, Anna Alperovich, Nishi Shah, Ellen Fraint, Richard J. Lin, Michael Scordo, Connie Lee Batlevi, Michal J. Besser, Parastoo B. Dahi, Ivetta Danylesko, Sergio Giralt, Brandon S. Imber, Elad Jacoby, Meirav Kedmi, Arnon Nagler, M. Lia Palomba, Mikhail Roshal, Gilles A. Salles, Craig Sauter, Noga Shem-Tov, Avichai Shimoni, Joachim Yahalom, Ronit Yerushalmi, Gunjan L. Shah, Abraham Avigdor, Miguel-Angel Perales, Roni Shouval
Summary: Persistence or recurrence of large B-cell lymphoma after CD19-CAR-T is common and associated with poor prognosis. Novel agents such as polatuzumab and lenalidomide may have potential as treatment options.
Letter
Oncology
David Qualls, Ariela Noy, David Straus, Matthew Matasar, Craig Moskowitz, Venkatraman Seshan, Ahmet Dogan, Gilles Salles, Anas Younes, Andrew D. Zelenetz, Connie Lee Batlevi
LEUKEMIA & LYMPHOMA
(2023)
Review
Cell Biology
Mostafa Ejtehadifar, Sara Zahedi, Paula Gameiro, Jose Cabecadas, Maria Gomes da Silva, Hans C. Beck, Ana Sofia Carvalho, Rune Matthiesen
Summary: Mass spectrometry-based proteomics has identified proteins as diagnostic, prognostic, and druggable targets in diffuse large B cell lymphoma. We reviewed these studies and extracted the most consistently significantly regulated proteins, including interferon regulatory factor4, annexinA5, and nucleobindin1.
Article
Oncology
Serena Zheng, Kanika Gupta, Piyush Goyal, Reiko Nakajima, Laure Michaud, Connie Lee Batlevi, Paul A. Hamlin, Steven Horwitz, Anita Kumar, Matthew J. Matasar, Alison J. Moskowitz, Craig H. Moskowitz, Ariela Noy, M. Lia Palomba, David J. Straus, Gottfried Von Keudell, Lorenzo Falchi, Joachim Yahalom, Andrew D. Zelenetz, Anas Younes, Gilles Salles, Heiko Schoeder, Erel Joffe
Summary: This study discusses the limitations of using interim PET for decision-making and prognosis in the frontline management of Hodgkin's lymphoma. It presents data suggesting that patients who continue treatment with ABVD despite not achieving a complete metabolic response on interim PET may have better outcomes than previously thought. The study also compares the performance of different methods for evaluating PET positivity. Overall, the results indicate that a subset of patients can continue ABVD treatment without a poor outcome, regardless of the criteria for PET2 positivity.
Article
Oncology
Gloria Margiotta-Casaluci, Sara Bigliardi, Federica Cocito, Erika Meli, Luigi Petrucci, Maura Nicolosi, Ombretta Annibali, Carola Boccomini, Valentina Bozzoli, Alessia Castellino, Federica Cattina, Natalia Cenfra, Sabino Ciavarella, Sofya Kovalchuk, Francesco Rotondo, Angelo Fama, Jacopo Olivieri, Francesco Zaja
Summary: In patients with grade 3A follicular lymphoma (FL), both bendamustine plus rituximab (R-B) and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHOP) have shown to be effective first-line treatment options. Although R-B group achieved a better complete remission rate than R-CHOP group, there was no significant difference in progression-free survival between the two groups. The overall survival was significantly longer with R-CHOP treatment, but this difference was not statistically significant after adjustment for age.
FRONTIERS IN ONCOLOGY
(2023)
Editorial Material
Hematology
Martin Dreyling, Martina Manni, Massimo Federico
Review
Oncology
Kim M. Linton, Lena Specht, Astrid Pavlovsky, Carrie A. Thompson, Eva Kimby, Daphne de Jong, Loretta J. Nastoupil, Anne-Segolene Cottereau, Carla Casulo, Clementine Sarkozy, Jessica Okosun
Summary: Follicular lymphoma, the most common indolent lymphoma in western countries, has a favorable prognosis but includes high-risk groups with poor outcomes. This review discusses recent updates in risk stratification and treatment approaches, including upfront treatment for limited and advanced stage follicular lymphoma, as well as options for relapsed, refractory disease. It also highlights the need for precise and prospective selection of optimal treatment based on varying risks, which may be achieved through a better understanding of the biology of different phenotypes and improved imaging and biomarker-based tools.
HEMATOLOGICAL ONCOLOGY
(2023)
Article
Oncology
Carla Minoia, Simonetta Viviani, Erica Silvestris, Simone Palini, Francesca Parissone, Giuseppe De Palma, Anna Fedina, Gennaro Cormio, Attilio Guarini, Guido Gini, Luigi Montano, Francesco Merli, Fedro Alessandro Peccatori
Summary: This study provides practical recommendations for fertility preservation and monitoring for lymphoma patients at different stages of the disease. Through expert panel discussions and literature review, a series of questions and statements were identified and a consensus was reached.
FRONTIERS IN ONCOLOGY
(2023)
Article
Hematology
Ana Carolina Freitas, Tiago Maia, Joana Desterro, Francesca Pierdomenico, Albertina Nunes, Isabelina Ferreira, Jose Cabecadas, Maria Gomes da Silva
Summary: Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are a diverse group of diseases that are increasingly classified based on recurrent genetic abnormalities. Chromosomal translocations involving meningioma 1 (MN1) and ETS variant 6 (ETV6) genes are rare but common in myeloid neoplasms. We present a case of MDS/MPN with neutrophilia that developed an extramedullary T-lymphoblastic crisis with the t(12;22)(p13;q12) translocation as the only cytogenetic abnormality. This case shares characteristics with myeloid/lymphoid neoplasms with eosinophilia and highlights the importance of molecular characterization in classification and prognostic stratification.
HEMATOLOGY REPORTS
(2023)
Meeting Abstract
Cell Biology
Jairo Eduardo Nino Ramirez, Miguel Alcoceba, Nieves Gutierrez-Zufiaurre, Miguel Marcos, Rocio Bartol Sanchez, Rocio Eiros, Maria Garcia-Alvarez, Pilar Terradillos Sanchez, Daniel Presa, Juan Luis Munoz, Amparo Lopez Bernus, Eugenia Lopez Sanchez, David Gonzalez-Calle, Pedro Luis Sanchez, Olga Compan Fernandez, Marcos Gonzalez, Ramon Garcia-Sanz, Francisco Boix
Meeting Abstract
Cell Biology
Jairo Eduardo Nino Ramirez, Francisco Javier Gil-Etayo, Isabel Jimenez Hernaz, Pilar Terradillos Sanchez, Ariadna Vicente Parra, Ana Balanzategui, Miguel Bastos Boente, Miguel Alcoceba, Ramon Garcia-Sanz, Amalia Tejeda Velarde
Meeting Abstract
Cell Biology
Jairo Eduardo Nino Ramirez, Francisco Javier Gil-Etayo, Isabel Jimenez Hernaz, Pilar Terradillos Sanchez, Ariadna Vicente Parra, Ana Balanzategui, Miguel Bastos Boente, Miguel Alcoceba, Ramon Garcia-Sanz, Amalia Tejeda-Velarde
Meeting Abstract
Cell Biology
Jairo Nino-Ramirez, Alejandro Medina, Estrella Arnes-Moreta, Ana Balanzategui, Rocio Corral, Alicia Anton, Maria Garcia-Alvarez, Rebeca Maldonado, Miguel Bastos-Boente, Igor de la Torre, Nerea H. Vidana, Cristina Jimenez, Maria Eugenia Sarasquete, M. Carmen Chillon, Montserrat Hernandez-Ruano, Sandra M. Lucas, Ana Isabel Sanchez-Gonzalez, Inmaculada Sanchez-Villares, Onica Gonzalez-Calle, Almudena Navarro-Bailon, Francisco Boix, F. Javier Gil-Etayo, Amalia Tejeda-Velarde, Ramon Garcia-Sanz, Miguel Alcoceba